



### SECTOR EXPERTISE

Unlike generalist firms, we concentrate solely on healthcare investment and transaction advisory



### GLOBAL NETWORK

We have been involved in transactions in 36 countries on 6 continents



### 360° APPROACH

As an investor; operator; and advisor, we offer perspectives from a complete spectrum of experiences



### MAXIMIZED OUTCOMES

We understand the necessity for the alignment of interest throughout the capital structure

transaction range:  
**\$25 million**  
to **\$1 billion+**

#### TYPES OF ADVISORY WORK

Mergers & Acquisitions  
Licensing / Partnering  
Equity Capital  
Debt Capital  
Strategic Consulting

#### SECTOR FOCUS

Pharmaceuticals  
Consumer Health / OTC  
Pharma Services  
Healthcare IT  
Medical Device / Diagnostics

## SELECT TOMBSTONES

2015  
**\$3,500,000,000**

Bourne Partners served as financial advisor to AMCo and Cinven in the sale of AMCo to Concordia Healthcare

BOURNE PARTNERS

2015  
**\$1,200,000,000**

Bourne Partners served as the exclusive financial advisor to Covis Pharma in the sale of the majority of its assets to Concordia Healthcare

BOURNE PARTNERS

2015  
**\$20,000,000**

Bourne Partners served as the exclusive financial advisor to Covis Pharma in its acquisition of one product from Shionogi

BOURNE PARTNERS

2015  
**\$8,500,000**

Bourne Partners served as the exclusive financial advisor to YASOO Health in the sale of AquADEKs to Allergan

BOURNE PARTNERS

**\$4.7 bn**  
deals in 2015

## SELECT CLIENTS & COUNTERPARTIES



Investment banking services are provided by Bourne Partners Securities, LLC, member FINRA and SIPC

### MERCHANT BANKING

<p>2015</p> <p><b>\$1,200,000,000</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Covis Pharma in the sale of the majority of its assets to Concordia Healthcare</p> <p><b>BOURNE PARTNERS</b></p>	<p>2015</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Tanner Pharma Group in its merger with BurnsAdler Pharmaceuticals</p> <p><b>BOURNE PARTNERS</b></p>	<p>2014</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as the exclusive financial advisor to OrphanCanada in its sale to Knight Therapeutics</p> <p><b>BOURNE PARTNERS</b></p>	<p>2011</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Covis Pharma in its initial equity raise from Cerberus and other investors</p> <p><b>BOURNE PARTNERS</b></p>	<p>2008</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as the exclusive financial advisor to BPAA in its acquisition of TheraMed Corporation</p> <p><b>BOURNE PARTNERS</b></p>
--	---	---	--	---

### BUYER REPRESENTATION

<p>2015</p> <p><b>\$20,000,000</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Covis Pharma in its acquisition of one product from Shionogi</p> <p><b>BOURNE PARTNERS</b></p>	<p>2014</p> <p><b>\$55,000,000</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Covis Pharma in its acquisition of two products from WellSpring</p> <p><b>BOURNE PARTNERS</b></p>	<p>2014</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Covis Pharma in its acquisition of one product from AstraZeneca</p> <p><b>BOURNE PARTNERS</b></p>	<p>2012</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as the exclusive financial advisor to TheraMed in its licensing of Canadian rights to Gelfoam from Pfizer</p> <p><b>BOURNE PARTNERS</b></p>	<p>2008</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Desitin in its licensing of EU rights to sumatriptan DosePro from Zogenix</p> <p><b>BOURNE PARTNERS</b></p>
<p>2015</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Knight in its licensing of the Canadian rights to one product from Akorn</p> <p><b>BOURNE PARTNERS</b></p>	<p>2014</p> <p><b>\$22,000,000</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Covis Pharma in its acquisition of one product from Bayer</p> <p><b>BOURNE PARTNERS</b></p>	<p>2013</p> <p><b>\$220,000,000</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Covis Pharma in its acquisition of a portfolio of products from Sanofi</p> <p><b>BOURNE PARTNERS</b></p>	<p>2011</p> <p><b>\$65,000,000</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Covis Pharma in its acquisition of a portfolio of products from GSK</p> <p><b>BOURNE PARTNERS</b></p>	<p>2007</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Azur Pharma in its acquisition of Pharmelle</p> <p><b>BOURNE PARTNERS</b></p>

### SELLER REPRESENTATION

<p>2017</p> <p><b>\$50,000,000</b></p>  <p>Bourne Partners served as the exclusive financial advisor to ProPhase Labs, Inc. in the sale of Cold-EEZE brand to Mylan N.V.</p> <p><b>BOURNE PARTNERS</b></p>	<p>2015</p> <p><b>\$12,000,000</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Concordia in its divestiture of a portfolio of products to Teligent</p> <p><b>BOURNE PARTNERS</b></p>	<p>2015</p> <p><b>\$8,500,000</b></p>  <p>Bourne Partners served as the exclusive financial advisor to YASOO Health in the sale of AquADEKs to Allergan</p> <p><b>BOURNE PARTNERS</b></p>	<p>2012</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as the exclusive financial advisor to TheraMed in its sale to Tribute Pharmaceuticals</p> <p><b>BOURNE PARTNERS</b></p>	<p>2011</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as financial advisor to Supernus in its licensing of Epliga in certain Latin American countries to Stendhal</p> <p><b>BOURNE PARTNERS</b></p>
<p>2016</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Reliable Biopharmaceutical in its equity raise from Blue Diamond Capital</p> <p><b>BOURNE PARTNERS</b></p>	<p>2015</p> <p><b>\$3,500,000,000</b></p>  <p>Bourne Partners served as financial advisor to AMCo and Civen in the sale of AMCo to Concordia Healthcare</p> <p><b>BOURNE PARTNERS</b></p>	<p>2014</p> <p><b>\$20,000,000</b></p>  <p>Bourne Partners served as the exclusive financial advisor to NFI in its sale (including the Blue Emu brand) to UPM Pharmaceuticals</p> <p><b>BOURNE PARTNERS</b></p>	<p>2011</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as the exclusive financial advisor to TheraMed in its divestiture of two products to Valeant</p> <p><b>BOURNE PARTNERS</b></p>	<p>2011</p> <p><b>Undisclosed</b></p>  <p>Bourne Partners served as the exclusive financial advisor to Axcan in its sale of Photofrin and Photobarr to Pinnacle Biologics</p> <p><b>BOURNE PARTNERS</b></p>